ArcticZymes Technologies Announces Nomination of Dr. Frank Mathi
Tromsø, Norway - June 25, 2024 - ArcticZymes Technologies (OSE:AZT) is pleased
to announce the nomination of Dr. Frank Mathias as the new Chairman of the
Board.
Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the
cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler
Biopharma SE, which he successfully developed into a leading global, full
-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a
publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias
has held senior roles at leading global pharmaceutical companies, including
Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he
was awarded the "EY Entrepreneur of the Year" title in Germany. Dr. Mathias is a
pharmacist by training and completed his Doctorate in Pharmacy at Paris VI
University.
"We are very pleased to nominate Frank Mathias as our new Chairman of the
Board," said Jon R. Sandberg, Chairman of the Nomination Committee. "Frank
Mathias' extensive experience and visionary leadership make him the ideal
candidate to guide our company into its next phase of development,
commercialization and growth."
"I am honoured to join ArcticZymes at such a pivotal time," said Dr. Frank
Mathias. "The innovative enzyme solutions developed by ArcticZymes have made
significant contributions to advancements in biomanufacturing, enhancing
efficiency and quality across the industry. I look forward to contributing to
the company's continued success and collaborative growth."
to announce the nomination of Dr. Frank Mathias as the new Chairman of the
Board.
Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the
cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler
Biopharma SE, which he successfully developed into a leading global, full
-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a
publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias
has held senior roles at leading global pharmaceutical companies, including
Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he
was awarded the "EY Entrepreneur of the Year" title in Germany. Dr. Mathias is a
pharmacist by training and completed his Doctorate in Pharmacy at Paris VI
University.
"We are very pleased to nominate Frank Mathias as our new Chairman of the
Board," said Jon R. Sandberg, Chairman of the Nomination Committee. "Frank
Mathias' extensive experience and visionary leadership make him the ideal
candidate to guide our company into its next phase of development,
commercialization and growth."
"I am honoured to join ArcticZymes at such a pivotal time," said Dr. Frank
Mathias. "The innovative enzyme solutions developed by ArcticZymes have made
significant contributions to advancements in biomanufacturing, enhancing
efficiency and quality across the industry. I look forward to contributing to
the company's continued success and collaborative growth."
Redigert 25.06.2024 kl 22:47
Du må logge inn for å svare
JosefK
25.06.2024 kl 11:08
655
To måneder etter at Astra Zeneca dumper covid vaksinen, så bllir CEO for Oxford Biomedica styreformann i AZT.
Det kan se tilfeldig ut, men jeg tviler.
For det første så er OXB i fritt fall etter eventyr oppturen under Covid. Som CEO så har Frank Mathias mer enn nok å holde styr på. For det andre har OXB allerede vist sin interesse for SAN gjennom patentet fra 2019.
https://patents.google.com/patent/WO2019175600A1/en
Jeg har sluttet å tro på tilfeldigheter.
På meg virker det som Oxford Biomedica har et «come to jesus» øyeblikk. At de leser Jan Raa, tror jeg ingenting på, men Jan har advart mot kontaminering av vaksiner i årevis. Og det er fullstendig mulig at denne kjeden av events gir han rett i det.
Og for de med kort minne, OXB var partner til Astra zeneca i forbindelse med covid vaksinen.
JosefK
25.06.2024 kl 22:47
349
Koselig🤗 Man må nesten ta turen til London for å finne vett i kommentarfeltet. Jeg kunne tenke meg å svare, nei, det er ikke det. Se ellers kommentaren min ovenfor 👆🏻
gareth jones: Would someone like to comment on a CEO of a medium LSE company such as OXB takes on the role of chairman of another company. Please give examples. If there are many I will defer to the greater knowledge of this board but surely as CEO you need to put all your energy into OXB? I'm also still looking for the green shoots of a major announcement. Hoping daily to have missed the signs. Come on OXB, the future is brighter than ever.
Jeg setter forøvrig på hengelåsen. For det er svært lite vettige kommenterer og jeg er utsatt for hets. Admin har slettet noe hets, men jeg tviler på det er noen som greier å holde seg til topic, så stillheten bekrefter for meg at det er lite relevant å diskutere.